Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis
Open Access
- 21 September 2021
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 100 (6), 1316-1324
- https://doi.org/10.1016/j.kint.2021.08.025
Abstract
No abstract availableFunding Information
- National Institute for Health Research
- NIHR Imperial Biomedical Research Centre
This publication has 27 references indexed in Scilit:
- Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated VasculitisClinical Journal of the American Society of Nephrology, 2013
- Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up studyNephrology Dialysis Transplantation, 2012
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Histopathologic Classification of ANCA-Associated GlomerulonephritisJournal of the American Society of Nephrology, 2010
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisThe New England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- Microscopic Polyangiitis with Alveolar Hemorrhage A Study of 29 Cases and Review of the LiteratureMedicine, 2000
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis.BMJ, 1985